Chiasma completes enrollment for phase 3 CHIASMA OPTIMAL trial

Chiasma announced that it has completed enrollment of its international Phase 3 clinical trial, referred to as CHIASMA OPTIMAL. This trial is being conducted under a special protocol assessment, or SPA, agreement with the FDA to support potential regulatory approval in the United States of its investigational octreotide capsules, conditionally trade-named Mycapssa, for the maintenance therapy of adult patients with acromegaly. Chiasma exceeded target enrollment of 50 patients in the trial with a total of 56 acromegaly patients randomized in 17 countries worldwide, including 21 patients from the U.S.
https://thefly.com/landingPageNews.php?id=2798007